Edition:
United Kingdom

NantKwest Inc (NK.OQ)

NK.OQ on NASDAQ Stock Exchange Global Select Market

5.00USD
12 Dec 2017
Change (% chg)

$0.12 (+2.46%)
Prev Close
$4.88
Open
$4.93
Day's High
$5.06
Day's Low
$4.89
Volume
79,391
Avg. Vol
76,106
52-wk High
$8.43
52-wk Low
$2.71

Chart for

About

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or... (more)

Overall

Beta: --
Market Cap(Mil.): $405.94
Shares Outstanding(Mil.): 79.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Nantkwest announces publication of preclinical data of hank cell therapy

* Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials Source text for Eikon: Further company coverage:

25 Jul 2017

Earnings vs. Estimates